Alterations of gyrA, gyrB, and parC and Activity of Efflux Pump in Fluoroquinolone-resistant Acinetobacter baumannii
- PMID: 24159468
- PMCID: PMC3767088
- DOI: 10.1016/j.phrp.2011.11.040
Alterations of gyrA, gyrB, and parC and Activity of Efflux Pump in Fluoroquinolone-resistant Acinetobacter baumannii
Abstract
Objectives: This study investigated the fluoroquinolone-resistant mechanism of 56 clinical cases of A baumannii infection from 23 non-tertiary hospitals, collected between 2004 and 2006.
Methods: Susceptibility testing was performed by broth microdilution and Epsilometer test. Analyses of quinolone resistance-determining region (QRDR) were done by sequencing. The activity of the efflux pump was measured using inhibitors.
Results: The sequences from selected 56 isolates were divided into seven groups (I-VII) on the basis of mutations in gyrA (S83L), parC (S80L, S80W and S84K) and gyrB (containing the novel mutations E679D, D644Y and A677V). The 27 isolates with triple mutations in gyrA, gyrB and parC (groups IV-VII) showed higher levels of resistance to ciprofloxacin (minimal inhibitory concentration [MIC] of 16-256 μg/mL) than the 26 isolates with double mutations in gyrA and parC (groups II and III, MIC of 8-64 μ g/mL; p < 0.05). Alterations in the efflux pump were observed in four isolates with the parC S80L mutation (group II) or E84K mutation (group VII), but no effect was observed in an isolate with the parC S80 W mutation (group III).
Conclusion: These results suggest that triple mutations in clinical isolates of A baumannii contribute to the development of high levels of resistance to fluoroquinolones and that mutations in parC S80L or E84K (groups II and VII) may contribute to alterations in efflux pump activity in A baumannii.
Keywords: A baumannii; efflux pump fluoroquinolone resistance; gyrA; gyrB; parC.
Similar articles
-
Overexpression of Efflux Pumps, Mutations in the Pumps' Regulators, Chromosomal Mutations, and AAC(6')-Ib-cr Are Associated With Fluoroquinolone Resistance in Diverse Sequence Types of Neonatal Septicaemic Acinetobacter baumannii: A 7-Year Single Center Study.Front Microbiol. 2021 Mar 11;12:602724. doi: 10.3389/fmicb.2021.602724. eCollection 2021. Front Microbiol. 2021. PMID: 33776950 Free PMC article.
-
Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.Antimicrob Agents Chemother. 2004 Oct;48(10):3954-8. doi: 10.1128/AAC.48.10.3954-3958.2004. Antimicrob Agents Chemother. 2004. PMID: 15388458 Free PMC article.
-
Fluoroquinolone resistance conferred by gyrA, parC mutations, and AbaQ efflux pump among Acinetobacter baumannii clinical isolates causing ventilator-associated pneumonia.Acta Microbiol Immunol Hung. 2019 Dec 13;67(4):234-238. doi: 10.1556/030.66.2019.040. Acta Microbiol Immunol Hung. 2019. PMID: 31833383
-
Association between mutations in gyrA and parC genes of Acinetobacter baumannii clinical isolates and ciprofloxacin resistance.Iran J Basic Med Sci. 2015 Jun;18(6):623-6. Iran J Basic Med Sci. 2015. PMID: 26221488 Free PMC article.
-
Mechanisms of fluoroquinolone resistance: an update 1994-1998.Drugs. 1999;58 Suppl 2:11-8. doi: 10.2165/00003495-199958002-00003. Drugs. 1999. PMID: 10553699 Review.
Cited by
-
Comparative genotypic characterization related to antibiotic resistance phenotypes of clinical carbapenem-resistant Acinetobacter baumannii MTC1106 (ST2) and MTC0619 (ST25).BMC Genomics. 2023 Nov 17;24(1):689. doi: 10.1186/s12864-023-09734-2. BMC Genomics. 2023. PMID: 37978344 Free PMC article.
-
Effect of Phenylalanine-Arginine Beta-Naphthylamide on the Values of Minimum Inhibitory Concentration of Quinolones and Aminoglycosides in Clinical Isolates of Acinetobacter baumannii.Antibiotics (Basel). 2023 Jun 18;12(6):1071. doi: 10.3390/antibiotics12061071. Antibiotics (Basel). 2023. PMID: 37370390 Free PMC article.
-
Phenotypic and Molecular Characteristics of Carbapenem-Resistant Acinetobacter baumannii Isolates from Bulgarian Intensive Care Unit Patients.Microorganisms. 2023 Mar 29;11(4):875. doi: 10.3390/microorganisms11040875. Microorganisms. 2023. PMID: 37110301 Free PMC article.
-
Colistin potentiation in multidrug-resistant Acinetobacter baumannii by a non-cytotoxic guanidine derivative of silver.Front Microbiol. 2023 Jan 4;13:1006604. doi: 10.3389/fmicb.2022.1006604. eCollection 2022. Front Microbiol. 2023. PMID: 36687622 Free PMC article.
-
Development of Nanoparticle Adaptation Phenomena in Acinetobacter baumannii: Physiological Change and Defense Response.Microbiol Spectr. 2023 Feb 14;11(1):e0285722. doi: 10.1128/spectrum.02857-22. Epub 2023 Jan 10. Microbiol Spectr. 2023. PMID: 36625664 Free PMC article.
References
-
- Spence RP, Towner KJ. Frequencies and mechanisms of resistance to moxifloxacin in nosocomial isolates of Acinetobacter baumannii. J Antimicrob Chemother. 2003 Oct;52(4):687–90. - PubMed
-
- Vila J, Ruiz J, Goῇi P, Jimenez de Anta T. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother. 1997 Jun;39(6):757–62. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
